Krs-2 Antibody (RJ-5): sc-100449
- Krs-2 Antibody (RJ-5) is a mouse monoclonal IgG1 κ, cited in 2 publications, provided at 100 µg/ml
- raised against recombinant Krs-2 of human origin
- recommended for detection of Krs-2 of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Krs-2 Antibody (RJ-5). This work is in progress.
Krs-2 Antibody (RJ-5) is a mouse monoclonal IgG1 antibody that detects Krs-2 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Krs-2, also known as MST-2, is a member of the mammalian Ste20-like kinase family, which plays a crucial role in cellular signaling pathways that regulate cell growth, survival, and apoptosis. Krs-2 is primarily located in the cytoplasm and can translocate to the nucleus under certain conditions, which is significant for its function in mediating stress responses and promoting cell survival. Krs-2 is known to interact with various signaling molecules, including caspase-3, which Krs-2 activates, thereby influencing apoptotic pathways. Krs-2′s ability to phosphorylate substrates and itself is essential for regulatory functions in the MAPK signaling cascade, making Krs-2 a vital component in the cellular response to external stimuli. With broad species reactivity and versatility in multiple applications, anti-Krs-2 antibody (RJ-5) is an invaluable tool for researchers studying the intricate roles of this kinase in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Krs-2 Antibody (RJ-5) References:
- Cell biological manifestations of bisdioxopiperazines treatment of human tumor cell lines in culture. | Lu, DY., et al. 2010. Anticancer Agents Med Chem. 10: 657-60. PMID: 21235436
- STK3 is a therapeutic target for a subset of acute myeloid leukemias. | Camgoz, A., et al. 2018. Oncotarget. 9: 25458-25473. PMID: 29876001
- O-GlcNAc Transferase Suppresses Inflammation and Necroptosis by Targeting Receptor-Interacting Serine/Threonine-Protein Kinase 3. | Li, X., et al. 2019. Immunity. 50: 576-590.e6. PMID: 30770249
- O-GlcNAc Transferase Suppresses Inflammation and Necroptosis by Targeting Receptor-Interacting Serine/Threonine-Protein Kinase 3. | Li, X., et al. 2019. Immunity. 50: 1115. PMID: 30995496
- Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer. | Schirmer, AU., et al. 2022. Mol Ther. 30: 485-500. PMID: 34450249
- STK3 promotes gastric carcinogenesis by activating Ras-MAPK mediated cell cycle progression and serves as an independent prognostic biomarker. | Chen, B., et al. 2021. Mol Cancer. 20: 147. PMID: 34772410
- High Receptor-interacting Serine/Threonine-protein Kinase 3 (RIP3) Expression Serves as an Independent Poor Prognostic Factor for Triple-negative Breast Carcinoma. | Chung, Y., et al. 2022. Anticancer Res. 42: 2753-2761. PMID: 35489766
- Risk factors for venous thromboembolism (VTE) after adrenalectomy for adrenal cortical neoplasms. | Moore, MD., et al. 2022. J Surg Oncol. 126: 1176-1182. PMID: 35997946
- Genetic variants in Mammalian STE20-like protein kinase 2 were associated with risk of NSCL/P. | Xu, X., et al. 2023. Gene. 873: 147459. PMID: 37141954
- Newly identified stress-responsive protein kinases, Krs-1 and Krs-2. | Taylor, LK., et al. 1996. Proc Natl Acad Sci U S A. 93: 10099-104. PMID: 8816758
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Krs-2 Antibody (RJ-5) | sc-100449 | 100 µg/ml | $333.00 |